Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A potential priming strategy

Journal of Infectious Diseases

Volumn 191, Issue 8, 2005, Pages 1210-1215

  Stephenson, Iain ^a,c   Bugarini, Roberto ^b   Nicholson, Karl G ^c   Podda, Audino ^b   Wood, John M ^d   Zambon, Maria C ^e   Katz, Jacqueline M ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b CHIRON VACCINES   (Italy)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

^d NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^e CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; INFLUENZA H5N3 VACCINE; INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; AVIAN INFLUENZA; AVIAN INFLUENZA VIRUS H5N1; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS REACTION; DRUG DESIGN; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEROCONVERSION; STRAIN DIFFERENCE; VACCINATION; VIRUS PATHOGENESIS; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, VIRAL; CROSS REACTIONS; DUCKS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HONG KONG; HUMANS; INFLUENZA IN BIRDS; INFLUENZA VACCINES; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE; SINGAPORE; THAILAND; VACCINATION; VIETNAM;

EID: 17044380507     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/428948     Document Type: Article

References (15)

1. Potter CW. Chronicle of influenza pandemics. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of influenza. Oxford, UK: Blackwell, 1998:3-18.
2. Katz JM, Lim W, Buxton-Bridges C, et al. Antibody responses in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis 1999; 180:1763-70.
3. Peiris JSM, Yu WC, Leung CW, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004; 363:617-9.
4. Horimoto T, Fukuda N, Iwatsuki-Horimoto K, et al. Antigenic differences between H5N1 human influenza viruses isolated in 1997 and 2003. J Vet Med Sci 2004; 66:303-5.
5. Hien TT, Nguyen TL, Dung NT, et al. Avian influenza (H5N1) in 10 patients in Vietnam. New Engl J Med 2004; 350:1179-88.
6. World Health Organization. Disease alert: confirmed human cases of avian influenza H5N1. Available at: http://www.who.int/csr/disease/avian_influenza/en/ (Accessed 1 August 2004).
7. Li KS, Guan Y, Wang J, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004; 430:209-13.
8. Stephenson I, Nicholson KG, Wood JM, et al. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 2004; 4:499-509.
9. Nicholson KG, Colegate AC, Podda A, et al. Safety and antigenicity of nonadjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937-43.
10. Stephenson I, Nicholson KG, Colegate A, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/duck/Singapore/97 vaccine in a primed human population. Vaccine 2003; 21:1687-93.
11. Meiklejohn G, Eickhoff TC, Graves P. Antigenic drift and efficacy of influenza virus vaccines. J Infect Dis 1978; 138:618-24.
12. Rowe T, Abernathy RA, Primmer JH, et al. Detection of antibody to avian influenza (H5N1) virus in human sera by using a combination of serological assays. J Clin Microbiol 1999; 37:937-43.
13. Tumpey T, Renshaw M, Clements JD, Katz JM. Mucosal delivery of inactivated influenza vaccine induces B cell dependent heterosubtypic cross protection against lethal influenza A H5N1 virus infection. J Virol 2001; 75:5141-50.
14. Sambhara S, Kurichh A, Miranda R, et al. Heterosubtypic immunity against human influenza A viruses including recently emerged avian H5 and H9 viruses induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocytes and macrophage function. Cell Immunol 2001; 211:143-53.
15. Okuno Y, Tanaka K, Baba K, et al. Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system. J Clin Microbiol 1990; 28:1308-13.